FARGO: A randomised, phase IIa, multi-centre, placebo-controlled trial of FAecal microbiota transplantation in primaRy sclerosinG chOlangitis (FARGO)

Research summary

FARGO is a randomised,phase IIa,multi-centre,placebo-controlled,single-blind,parallel group trial investigating the activity of FMT in the treatment of patients with PSC. The primary objective is to determine the effect of FMT,administered via colonoscopy (single dose) and via enema (once weekly for seven weeks),on circulating ALP values measured at 48 weeks.

Principal Investigator

Dr Emma Culver

Contact us

Email: ouh-tr.ctfresearch@nhs.net

IRAS number

1006645